Action DRNA DICERNA PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Dicerna Pharmaceuticals, Inc.

Actions

DRNA

US2530311081

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Dicerna Pharmaceuticals : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - Form 8-K
PU
DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
BU
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
BU
Dicerna Pharmaceuticals : Novo Nordisk to Acquire Dicerna - Form 8-K
PU
DICERNA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Novo Nordisk to Acquire Dicerna
BU
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
BU
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
BU
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update - Form 8-K
PU
DICERNA PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Dicerna Pharmaceuticals: Q3 Earnings Snapshot
AQ
DICERNA PHARMACEUTICALS INC : Results of Operations and Financial Condition (form 8-K)
AQ
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
BU
Dicerna Presents PHYOX2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
AQ
 Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
BU
Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021
BU
Dicerna Pharmaceuticals : Announces Results for PHYOX4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
AQ
Dicerna Pharmaceuticals : Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
BU
Dicerna Pharmaceuticals : Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action DRNA
  4. Actualités Dicerna Pharmaceuticals, Inc.
  5. Communiqués